Ensifentrane:A new drug for chronic obstructive pulmonary diseases
10.13699/j.cnki.1001-6821.2024.05.022
- VernacularTitle:治疗慢性阻塞性肺疾病的新药Ensifentrine
- Author:
Rong-Fang XIE
1
;
Zhi-Hui LAN
Author Information
1. 江西中医药大学研究生院,江西南昌 330006
- Keywords:
Ensifentrine;
chronic obstructive pulmonary diseases;
phosphodiesterase 3/4 double inhibitor;
clinical trial
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(5):737-740
- CountryChina
- Language:Chinese
-
Abstract:
Ensifentrine is the first-class of dual inhibitors targeting phosphodiesterase 3 and 4(PDE3/4),a new bifunctional drug that can combine Bronchiectasis and anti-inflammatory activity in one molecule,and the only PDE3/4 inhibitor that successfully passed the Phase Ⅲclinical trial.Verona Pharma has submitted its marketing application to the Food and Drug Administration(FDA)as a COPD maintenance drug,It is expected to become the world's first new mechanism therapy for treating COPD in the past decade.Clinical trials have shown that Ensifentraine can improve lung function in COPD,while also having a wide range of anti-inflammatory effects,good tolerance,and generally mild adverse events,mainly headache,vomiting,etc.This article introduces the mechanism of action,pharmacodynamics,pharmacological effects,clinical research,and safety of Ensifentraine.
